Fabio Brodskyn

Dr. Fabio Brodskyn


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FMFatima Cristina Mendes de Matos
Fatima Cristina Mendes de Matos
Jose VartanianJose Vartanian
Jose Vartanian
JBJosé Carlos Barauna
José Carlos Barauna
ASAry Serrano Santos
Ary Serrano Santos
AMAchilles Alves de Levy Machado
Achilles Alves de Levy Machado
GMGiulianno Molina Melo
Giulianno Molina Melo
DEAR EDITOR AND COLLEAGUES, Concerning the article “Treatment strategies for low-risk papillary thyroid carcinoma”, published in the Archives of Endocrinology and Metabolism, the Brazilian Society of Head and Neck Surgery (SBCCP) has received with great concern the following statement: “In our opinion, either [partial thyroidectomy] or lobectomy is a good option for patients in Brazil, especially considering the limited number of head and neck surgeons with high surgical volume in the country” (). […] Thyroid surgery volume – A statement [...] DEAR EDITOR AND COLLEAGUES, Concerning the article “Treatment strategies for low-risk papillary thyroid carcinoma”, published in the Archives of Endocrinology and Metabolism, the Brazilian Society of Head and Neck Surgery (SBCCP) has received with great concern the following statement: “In our opinion, either [partial thyroidectomy] or lobectomy is a good option for patients in Brazil, especially considering the limited number of head and neck surgeons with high surgical volume in the country” (). […] Thyroid surgery volume – A statement

27 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
GMGiulianno Molina Melo
Giulianno Molina Melo
MNMurilo Catafesta Neves
Murilo Catafesta Neves
RRRafael Dias Romero
Rafael Dias Romero
MRMarcello Rosano
Marcello Rosano
RMRodrigo Tadashi Martines
Rodrigo Tadashi Martines
OCOnivaldo Cervantes
Onivaldo Cervantes
Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common neoplasm in humans and the most frequent in Brazil (80% in the head and neck region, 20% mortality). Brazil is a world leader in organ transplants (more than 30,000 transplants in 2019). The risk of transplant patients (Tx) developing CSCC is 65–250 times higher, with deeper infiltration, advanced stage, higher local recurrence, occult metastases, and worse survival. Objective: To investigate the prognostic factors of locally advanced cutaneous squamous cell carcinoma (LACSCC) of the head and neck region in transplant patients. Methods: 16-year retrospective, single-center series of patients with LACSCC in the head and neck region who underwent surgical treatment. Clinical and Tx data, clinical/pathological stage, surgical treatment, parotid/regional and distant metastases, recurrence, and survival were analyzed. Results: 156 patients were included: 69.2% women, 65.3 years; mean primary size: 4.24 cm, 66% T3/T4 tumors, 71% grade 2/3 differentiation, 20.5% transplant recipients, follow-up: 33.6 months. The most affected regions were malar/nasal (28.8%) and auricular (19.2%). Surgeries included wide resection with reconstruction (58.9%), exenteration (14.1%), and temporalectomy (11.5%). Univariate analysis: Recurrence: immunosuppressor drugs (p = 0.009), transplanted (p = 0.006), compromised margin (p = 0.049); Mortality: immunosuppression (p = 0.028), total resection and reconstruction (p = 0.013), stage (8ed) III-IV (p < 0.001), compromised margin (p < 0.001), neck metastasis with extranodal extension (p = 0.018). Multivariate analysis: Recurrence: transplanted HR: 3.69 (p < 0.001), neck metastasis extranodal extension HR: 5.41 (p < 0.001), evolution to distant metastasis HR: 5.27 (p < 0.001); Mortality: neck metastasis extranodal extension HR: 1.94, (p = 0.032), compromised margins HR: 1.87 (p = 0.001). Main surgical procedures: temporalectomy HR: 2.83 (p = 0.007), major rhinectomy HR: 2.47 (p = 0.005); Worst overall survival: Tx compared to NonTx (p = 0.069); Worst survival with recurrence: Tx compared to NonTx (p = 0.005). Conclusions: The LACSCC and transplanted (immunosuppressed) group present low survival, worse prognosis; The formulation of specific guidelines to standardize treatment and predict outcomes on this population are strictly necessary.

12 May 2026 in Virchows Archiv
Verified
Journal Article
Closed access
FBFabio Brodskyn
Fabio Brodskyn
FVFlavia Facuri Valente
Flavia Facuri Valente
SLSusan Chow Lindsey
Susan Chow Lindsey
LCLuiz Antonio de Jesus Rocha Camargo
Luiz Antonio de Jesus Rocha Camargo
FCFabiano Callegari
Fabiano Callegari
MAMarcio Abrahao
Marcio Abrahao

10 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGiulianno Molina Melo
Giulianno Molina Melo
MNMurilo Catafesta Neves
Murilo Catafesta Neves
RRRafael Dias Romero
Rafael Dias Romero
MRMarcello Rosano
Marcello Rosano
RMRodrigo Tadashi Martines
Rodrigo Tadashi Martines
OCOnivaldo Cervantes
Onivaldo Cervantes
Background: Squamous cell carcinoma of the skin (SCC) is the second most common neoplasm in humans and the most frequent in Brazil (80% in the head and neck region, 20% mortality). Brazil is a world leader in organ transplants (more than 30,000 transplants in 2019). The risk of transplant patients (Tx) developing SCC is 65-250 times higher, with deeper infiltration, advanced stage, higher local recurrence, occult metastases and worse survival. Objective: To investigate the prognostic factors of locally advanced cutaneous squamous cell carcinoma (LASCC) of the head and neck region in transplant patients. Methods:16-year retrospective, single-center series of patients with LASCC in the head and neck region who underwent surgical treatment. Were analyzed: clinical and Tx data, clinical/pathological stage, surgical treatment, parotid/regional and distant metastases, recurrence and survival. Results: 156 patients were included: 69.2% women, 65.3 years; mean primary size: 4.24 cm, 66% T3/T4 tumors, 71% grade 2/3 differentiation, 20.5% transplant recipients, follow-up: 33.6 months. Most affected regions: malar/nasal (28.8%), auricular (19.2%). Surgeries: wide resection with reconstruction (58.9%), exenteration (14.1%), temporalectomy (11.5%). Univariate analysis: Recurrence: immunosuppressor drugs (p=0.009), transplanted (p=0.006), compromised margin (p=0.049), Mortality: immunosuppression (p=0.028), Total Resection and reconstruction (p=0.013), Stage(8ed) III-IV (p<0.001), compromised margin (p<0.001), neck metastasis with extranodal extension (p=0.018). Multivariate analysis: Recurrence: Transplanted HR:3.69 (p<0.001), Neck metastasis extranodal extension HR:5.41 (p<0.001), Evolution to Distant metastasis HR:5.27 (p<0.001); Mortality: Neck metastasis extranodal extension HR:1.94, (p=0.032), Compromised Margins HR:1.87 (p=0.001), Main Surgical Procedures: Temporalectomy HR:2.83 (p=0.007); Major Rhinectomy HR:2.47 (p=0.005); Worst Overall Survival: Tx compared to NonTx (p=0.069), Worst Survival with Recurrence: Tx compared to NonTx (p=0.005). Conclusions: The LASCC and Transplanted (immunosuppressed) group present low survival, worse prognosis, high risk of recurrence and mortality outcome, formulation of specific guidelines to standardize treatment and predict outcomes in this population are strictly necessary.